Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
Objective Immunotherapy has not yielded satisfactory therapeutic responses in gastric cancer (GC).However, targeting myeloid checkpoints holds promise for expanding the potential of immunotherapy.This study aims to evaluate the critical lexus rc4 role of Siglec-10+ tumor-associated macrophages (TAMs) in regulating antitumor immunity and to explore